维生素D缺乏与COVID-19住院风险升高相关:一项回顾性病例对照研究
该回顾性病例对照研究纳入英国西北部80 670名有血清25(OH)D检测结果者,比较COVID-19住院与非住院患者维生素D水平。结果显示住院患者25(OH)D中位数更低,25(OH)D<50 nmol/L者住院调整OR为2.3~2.4倍,但无超额死亡风险。
要点
- COVID-19住院患者血清25(OH)D中位数低于非住院患者。
- 25(OH)D<50 nmol/L者住院风险约为正常者的2.3~2.4倍。
- 维生素D不足或缺乏未伴随COVID-19超额死亡风险。
核心结论
- 维生素D缺乏与COVID-19住院风险升高相关。
- 广泛检测血清25(OH)D并治疗不足或缺乏可能降低该风险。
研究设计与样本
- 回顾性病例对照研究,纳入2020年4月1日至2021年1月29日英国西北部2个地区有血清25(OH)D检测结果者80 670人。
- 将既往12个月内最后一次25(OH)D水平分为缺乏(<25 nmol/L)和不足(25~50 nmol/L)。
主要发现
- 1808人因COVID-19住院,其中670人死亡。
- 主要队列中,非住院COVID-19患者25(OH)D中位数50.0 nmol/L(IQR 34.0-66.7),住院患者35.0 nmol/L(IQR 21.0-57.0),P<0.005。
- 验证队列中,非住院患者25(OH)D中位数47.1 nmol/L(IQR 31.8-64.7),住院患者33.0 nmol/L(IQR 19.4-54.1)。
- 经年龄、性别和季节调整后,25(OH)D<50 nmol/L者住院OR为正常者的2.3~2.4倍,无超额死亡风险。
关键数值与推荐
- 25(OH)D缺乏定义为<25 nmol/L,不足定义为25~50 nmol/L。
- 25(OH)D<50 nmol/L者COVID-19住院调整OR为2.3~2.4倍。
临床怎么用
- 对内分泌科患者可关注血清25(OH)D水平,识别不足或缺乏者。
- 治疗维生素D不足或缺乏可能有助于降低COVID-19住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: One risk factor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is postulated to be vitamin D deficiency. To better understand the role of vitamin D deficiency in the disease course of COVID-19, we undertook a retrospective case-control study in North West England. OBJECTIVE: To examine whether hospitalization with COVID-19 is more prevalent in individuals with lower vitamin D levels. METHODS: The study included individuals with test results for serum 25-hydroxyvitamin D (25[OH]D) between April 1, 2020, and January 29, 2021, from 2 districts in North West England. The last 25(OH)D level in the previous 12 months was categorized as "deficient" if less than 25 nmol/L and "insufficient" if 25 to 50 nmol/L. RESULTS: The study included 80 670 participants. Of these, 1808 were admitted to the hospital with COVID-19, of whom 670 died. In a primary cohort, median serum 25(OH)D in nonhospitalized participants with COVID-19 was 50.0 nmol/L (interquartile range [IQR], 34.0-66.7) vs 35.0 nmol/L (IQR, 21.0-57.0) in those admitted with COVID-19 (P < 0.005). In a validation cohort, median serum 25(OH)D was 47.1 nmol/L (IQR, 31.8-64.7) in nonhospitalized vs 33.0 nmol/L (IQR, 19.4-54.1) in hospitalized patients. Age-, sex-, and season-adjusted odds ratios for hospital admission were 2.3 to 2.4 times higher among participants with serum 25(OH)D <50 nmol/L compared with those with normal serum 25(OH)D levels, without excess mortality risk. CONCLUSION: Vitamin D deficiency is associated with higher risk of COVID-19 hospitalization. Widespread measurement of serum 25(OH)D and treatment of insufficiency or deficiency may reduce this risk.
引用
- Jude EB, Ling SF, Allcock R, et al. Vitamin D Deficiency Is Associated With Higher Hospitalization Risk From COVID-19: A Retrospective Case-control Study. J Clin Endocrinol Metab. 2021. PMID: 34139758. doi:10.1210/clinem/dgab439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。